UK Industry Welcomes Post-Brexit ‘Windsor Framework’ For Northern Ireland
UK consumer healthcare industry association, PAGB, has welcomed the landmark “Windsor Framework” agreed by the UK and the EU, which proposes that medicines will take a “green lane” from Great Britain to Northern Ireland, while the UK regulator, MHRA, will have UK-wide responsibility for all drug approvals.
You may also be interested in...
OTC medicines manufacturers operating in Great Britain or Northern Ireland must add a “UK only” label to outer packaging to prevent their OTC products being exported into any part of the European Union. This new packaging artwork can be submitted to the MHRA anytime from now but must be submitted prior to 31 December 2024, advises Jenson R+.
UK consumer healthcare association chief Michelle Riddalls tells House of Lords peers that over half of OTC medicines could disappear from Northern Ireland's pharmacy and grocery shelves because of regulatory burdens imposed by the Brexit-related Northern Ireland Protocol.
German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.